Inhibition of TLR7 and 8: A new way to treat lupus?

Enpatoran, a toll-like receptor (TLR) 7 and 8 inhibitor, showed potential in patients with active systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Although the primary endpoint of the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) dose response was not met, response rates and secondary outcomes support further investigations. The phase 2 WILLOW study (NCT05162586) included participants with active SLE and CLE evaluated within 2 cohorts [1]. Cohort A met its primary endpoint of a significant dose-response in CLE Disease Area and Severity Index-Activity (CLASI-A). The findings from cohort B, presented by Prof. Eric Morand (Monash University, Australia), evaluated enpatoran’s impact on the BICLA response at week 24 in participants with active SLE (BILAG 1A/2B) receiving standard-o...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 18 June 20258 August 2025